Results 11 to 20 of about 396 (132)

Developments in the Management of Growth Hormone Deficiency: Clinical Utility of Somapacitan [PDF]

Drug Design, Development and Therapy
Bradley S Miller,1 Jo Blair,2 Reiko Horikawa,3 Agnès Linglart,4– 7 Kevin CJ Yuen8 1Division of Pediatric Endocrinology, University of Minnesota Medical School, MHealth Fairview Masonic Children’s Hospital, Minneapolis, MN, USA; 2Department of Paediatric ...
Miller BS, Blair J, Horikawa R, Linglart A, Yuen KC   +4 more
doaj   +5 more sources

Somapacitan-Induced Reversible Lipoatrophy in an Adult Woman With Hypopituitarism [PDF]

Pituitary
Abstract Background Lipoatrophy is rare adverse event (AE) in daily recombinant human growth hormone (rhGH). Data on lipoatrophy in newly developed long-acting GH (LAGH) are scarce. We report the first case of lipoatrophy in adult patient treated with LAGH somapacitan. Case presentation
Andrej Janež, Matej Rakusa, Mojca Jensterle Sever   +2 more
exaly   +5 more sources

Once-Weekly Somapacitan as an Alternative Management of Growth Hormone Deficiency in Prepubertal Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trial

Children
Growth hormone treatment has effectively restored normal growth in children with growth hormone deficiency (GHD); however, it poses challenges in compliance with a daily growth hormone injection regimen, leading to low adherence and persistence rates ...
Muhammad Iqhrammullah, Fajar Fakri, Cut Alifiya Nazhifah   +2 more
exaly   +4 more sources

Patients with Growth-Related Disorders and Caregivers Prefer the Somapacitan Device to the Somatrogon Device: Results from a Randomized Crossover Study Assessing Device Preference and Ease of Use Following Simulated Injections [PDF]

Medical Devices: Evidence and Research
Shahid Akhtar,1 Birgitte Berg,2 Johan Medina,3 Maya Nicole Gonczi,4 Sophie Hamilton,5 Emily Hildebrand,4 Nicky Kelepouris,6 Jesper Skov Neergaard,7 Claus Sværke,8 Gitte Ter-Borch,2 Niklas Kahr Rasmussen3 1Devices & Digital Health, Novo Nordisk A/S ...
Akhtar S, Berg B, Medina J, Gonczi MN, Hamilton S, Hildebrand E, Kelepouris N, Neergaard JS, Sværke C, Ter-Borch G, Rasmussen NK   +10 more
doaj   +4 more sources

Identification of Binding Sites on Human Serum Albumin for Somapacitan, a Long-Acting Growth Hormone Derivative [PDF]

Biochemistry, 2020
Abstract Somapacitan, a human growth hormone derivative that binds reversibly to albumin, was investigated for human serum albumin (HSA) and HSA domain binding. Isothermal titration calorimetry (ITC) binding profiles showed high-affinity binding (∼100–1000 nM) of one somapacitan molecule and low-affinity binding (∼1000–10000 nM) of ...
Eva Johansson, Anders D. Nielsen, Helle Demuth, Charlotte Wiberg, Christine B. Schjødt, Tao Huang, Jianhe Chen, Sanne Jensen, Jørgen Petersen, Peter Thygesen   +9 more
openaire   +5 more sources

Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency

Pituitary, 2022
Abstract Purpose The long-term effects of long-acting growth hormone (LAGH) analogues on glucose metabolism in adult growth hormone deficiency (AGHD) are not known. We investigated the impact of LAGH somapacitan, administered once-weekly, on glucose metabolism in patients with AGHD. Methods
Yutaka Takahashi, Beverly M. K. Biller, Hidenori Fukuoka, Ken K. Y. Ho, Michael Højby Rasmussen, Navid Nedjatian, Claus Sværke, Kevin C. J. Yuen, Gudmundur Johannsson   +8 more
openaire   +3 more sources

Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety, and Treatment/Disease Burden Results From REAL 3

The Journal of Clinical Endocrinology & Metabolism, 2023
Abstract Context Growth hormone deficiency (GHD) in children is currently treated with daily injections of GH, which can be burdensome for patients and their parents/guardians. Somapacitan is a GH derivative in development for once-weekly treatment of GHD.
Lars Sävendahl, Tadej Battelino, Michael Højby Rasmussen, Meryl Brod, Sebastian Röhrich, Paul Saenger, Reiko Horikawa   +6 more
openaire   +3 more sources

Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial [PDF]

European Journal of Endocrinology, 2018
Objective Somapacitan is a reversible albumin-binding growth hormone (GH) derivative, developed for once-weekly administration. This study aimed to evaluate the safety of once-weekly somapacitan vs once-daily Norditropin ® .
Gudmundur Johannsson, Ulla Feldt-Rasmussen, Ida Holme Håkonsson, Henrik Biering, Patrice Rodien, Shigeyuki Tahara, Andrew Toogood, Michael Højby Rasmussen, _ _, _ _, Henrik Biering, Wolfram Karges, Alexander Mann, Jens Sandahl Christiansen, Troels Krarup Hansen, Marianne Andersen, Ulla Feldt-Rasmussen, Sine Borresen, Patrice Rodien, Françoise Borson-Chazot, Véronique Kerlan, Bertrand Cariou, Bruno Verges, Shigeyuki Tahara, Akira Matsuno, Koji Takano, Tetsuya Tagami, Yutaka Takahashi, Toshikazu Takahashi, Masahiro Yamamoto, Gudmundur Johannsson, Charlotte Höybye, Eva-Marie Erfurth, William Drake, Claire Higham, Robert Murray, Andrew Toogood, Antonia Brooke   +37 more
core   +6 more sources

Dose–exposure–IGF-I response of once-weekly somapacitan in adults with GH deficiency

European Journal of Endocrinology, 2022
Abstract Objective Growth hormone (GH) replacement therapy in patients with adult growth hormone deficiency (AGHD) is individually titrated due to variable dose–responses among patients. The aim of this study was to provide clinical guidance on dosing and titration of the novel long-acting GH ...
Rasmus Juul Kildemoes, Christian Hollensen, Beverly M K Biller, Gudmundur Johannsson, Yutaka Takahashi, Michael Højby Rasmussen   +5 more
core   +4 more sources

Seven-year Safety and Efficacy of Somapacitan in Children With GH Deficiency: Final Results From REAL 3. [PDF]

J Endocr Soc
Abstract Background Somapacitan is a once-weekly GH treatment that has shown efficacy and safety profiles equivalent to daily GH in children with GH deficiency (GHD). Objective To investigate long-term safety ...
Sävendahl L, Battelino T, Højby M, Leunbach T, Saenger P, Silverman L, Horikawa R.   +6 more
europepmc   +6 more sources